RADNET INC (RDNT)

Sector: Health Care

    Home/Companies/RDNT/Annual Meeting

2026 Annual Meeting Analysis

RADNET INC · Meeting: June 2, 2026

Policy v1.2medium confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

6

Directors AGAINST

0

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Six Nominees as Directors to Hold Office Until the 2027 Annual Meeting of Stockholders

6 FOR
✓ FOR
Howard G. Berger, M.D.

RadNet's 3-year price return of 111.9% outperforms the peer group median by +108.3 percentage points, far exceeding the 50pp threshold required to trigger a No vote for a strong-positive TSR company; no overboarding, attendance, or independence concerns apply to this long-tenured CEO-Chairman.

✓ FOR
A. Gregory Sorensen, M.D.

Dr. Sorensen joined the board in August 2023, which is less than 24 months before the meeting date, so he is exempt from the TSR underperformance trigger under policy; he brings relevant AI, medical imaging, and healthcare industry expertise with no overboarding concerns.

✓ FOR
Laura P. Jacobs

The TSR trigger does not fire given RadNet's exceptional 3-year outperformance versus peers (+108.3pp vs. 50pp threshold); Ms. Jacobs is independent, serves on appropriate committees, and brings deep healthcare management consulting experience.

✓ FOR
Lawrence L. Levitt

The TSR trigger does not apply given RadNet's strong outperformance; Mr. Levitt is a CPA and qualified audit committee financial expert with longstanding financial expertise, independent, and shows no overboarding or attendance issues.

✓ FOR
Gregory E. Spurlock

The TSR trigger does not apply given RadNet's strong outperformance; Mr. Spurlock is independent and brings directly relevant radiology and healthcare operations experience with no attendance or overboarding flags.

✓ FOR
David L. Swartz

The TSR trigger does not apply given RadNet's strong outperformance; Mr. Swartz is a retired CPA serving as Lead Independent Director and Audit Committee Chair, is independent, and has extensive financial accounting experience with no concerns.

All six director nominees receive a FOR vote. RadNet's 3-year price return of 111.9% outperforms its disclosed peer group median by approximately 108 percentage points, well above the 50-percentage-point threshold that would trigger adverse votes for a company with strong positive returns. Dr. Sorensen, who joined in August 2023, is within the 24-month new-director exemption window. The board includes a disclosed skills matrix, two audit committee financial experts, all independent non-executive directors on audit and compensation committees, and no overboarding or material attendance issues.

Say on Pay

✓ FOR

CEO

Howard G. Berger, M.D.

Total Comp

$12,087,934

Prior Support

83%%

time based only equity no forward performance conditions

CEO total compensation of approximately $12.1 million consists of a $3 million base salary and a $9 million restricted stock grant (with time-based vesting only), which raises a concern about the absence of forward-looking performance conditions on the equity component; however, the 2023 grants included AEBITDA-based performance stock units and options, and the company does use a clawback policy. RadNet delivered outstanding results — 3-year stock price return of 111.9% versus a peer median of 3.6%, and revenue growth of 11.5% in 2025 — meaning the pay-for-performance alignment check strongly favors approval since variable pay above benchmark is more than justified by dramatically superior shareholder returns. Prior Say on Pay support was 83% and 89% in successive years, well above the 70% threshold that would require a remediation response, and the overall compensation structure is reasonable for a founder-CEO of a $4.5 billion company delivering exceptional long-term performance.

Auditor Ratification

✓ FOR

Auditor

Ernst & Young LLP

Tenure

N/A

Audit Fees

N/A

Non-Audit Fees

N/A

The proxy filing does not disclose an auditor fee table with audit and non-audit fee figures, so the non-audit fee ratio trigger cannot be evaluated; auditor tenure is not disclosed in the available filing text, so the tenure trigger cannot fire per policy; Ernst & Young LLP is a Big 4 firm fully appropriate for a $4.5 billion market cap company, and no material restatements are indicated, so the default FOR vote stands.

Overall Assessment

The 2026 RadNet annual meeting ballot contains four proposals: election of six directors, ratification of Ernst & Young as auditor, an advisory Say on Pay vote, and approval of an amended equity incentive plan. All standard proposals receive FOR votes — the director slate is supported by RadNet's exceptional 3-year stock outperformance of roughly 108 percentage points above its peer group median, the Say on Pay program is supported by strong pay-for-performance alignment despite time-based-only equity vesting mechanics, and the auditor ratification is supported by Ernst & Young's Big 4 status with no fee or restatement concerns identified from the available filing data.

Filing date: April 20, 2026·Policy v1.2·medium confidence

Compensation Peer Group

16 companies disclosed in 2026 proxy filing

ACHCAcadia Healthcare Company, Inc.
AHCOAdaptHealth Corp
ADUSAddus HomeCare Corporation
AMEDAmedisys, Inc.
ASTHAstrana Health, Inc.
AVAHAveanna Healthcare Holdings Inc.
CHEChemed Corporation
CONConcentra Group Holdings Parent, Inc.
EHCEncompass Health Corporation
OPCHOption Care Health, Inc.
PACSPACS Group, Inc.
MDPediatrix Medical Group, Inc.
SEMSelect Medical Holdings Corporation
SGRYSurgery Partners, Inc.
ENSGThe Ensign Group, Inc.
USPHU.S. Physical Therapy, Inc.